Jinbo Bio, a leading player in the recombinant collagen sector, recently published its interim report for the first half of 2026, revealing a notable setback in its growth trajectory. The financial data shows the company generated revenue of RMB 771 million during the period, a year-on-year decline of 10.20%, while net profit attributable to shareholders fell 28.20% to RMB 281 million. This marks the first simultaneous drop in both revenue and profit for a first-half period in five years, with gross margin also retreating from 90.68% to 84.70%, signaling an interruption to what had been a rapid growth narrative. Although the functional skincare segment posted a 22.93% revenue increase, it was insufficient to offset the downturn in the core medical device business, leaving clear near-term earnings pressure in view.

Medical devices serve as the foundational revenue pillar for Jinbo Bio, contributing the vast majority of total sales. In the first half of 2026, this segment generated RMB 595 million, down 15.95% year-on-year, with single-material and composite-material medical device products experiencing revenue declines of 13.23% and 43.87%, respectively. The performance slump has exposed multiple operational concerns. To reward the market, the company offered price discounts on its core implantable collagen products, directly squeezing profit margins. Additionally, following the capitalization of new production facilities, capacity has yet to be fully utilized, and rising depreciation and amortization costs have pushed up product expenses. The sharp contraction in composite-material medical device revenue is attributed to internal adjustments within the business team, reflecting how organizational restructuring has disrupted core operations.

Regional sales performance shows severe divergence, with North China and South China recording modest growth, while West China and Central China saw revenue plunge 66.17% and 37.44%, respectively. The report attributes this to client adjustments, which indirectly highlights an unstable customer base and a heavy reliance on a small number of clients in certain regions, where any shift in customer demand can trigger dramatic volatility. The skincare business is growing rapidly, but hidden risks lurk beneath the surface. Single-ingredient skincare products surged 95.51% in revenue, yet operating costs climbed 123.65%, driven largely by marketing expenses tied to partnerships with major livestream hosts. Meanwhile, composite-ingredient skincare products implemented concessionary pricing to satisfy key client procurement needs, further elevating operating costs. The skincare segment's gross margin stands at only 67.43%, significantly lower than that of the medical device business, indicating that this emerging growth area remains weakly profitable and unlikely to shoulder the company's overall profit burden in the near term.

Despite retaining a relatively high gross margin within the industry, Jinbo Bio is finding that high margins alone can no longer sustain high growth, as intensifying competition in the sector gradually erodes its former advantages. On the expense front, selling expenses reached RMB 182 million in the first half, accounting for 23.57% of revenue, roughly flat with prior levels. However, R&D spending declined year-on-year to RMB 42.86 million, representing just 5.56% of revenue. With technology iteration accelerating across the recombinant collagen space, a contraction in R&D investment could weaken the company's long-term technical moat, casting doubt on its ability to compete effectively against rivals. Looking at the broader industry, the recombinant collagen market still offers substantial headroom, with projections suggesting the total market size could surpass RMB 100 billion by 2027, and functional skincare continues to post impressive growth rates. Yet competition is heating up, with raw material price wars, a fiercely contested skincare market, and lingering uncertainty from past industry controversies adding to the challenges. Among peers, Giant Biogene maintains its position as the revenue leader, while Trauer Bio remains in a scale-building phase, intensifying competitive pressures. For Jinbo Bio, its high-margin advantage is increasingly being offset by weakening growth momentum. Overseas business achieved slight growth, but total revenue from international markets is merely RMB 3.12 million, far too small to serve as a meaningful buffer against domestic headwinds.

For Jinbo Bio, the growth in its skincare segment cannot, for now, compensate for the decline in its core medical device business. Navigating the industry cycle will ultimately depend on technological and R&D strength. Stabilizing the medical device foundation, optimizing the customer and pricing structure, and balancing new business growth against profitability are the central challenges this recombinant collagen leader must address in the period ahead.